Roopinder Gillmore - Concepedia

Author

Roopinder Gillmore

Also Known As

Debashis Sarker, Fanourios Georgiades, Gillmore Roopinder, Gillmore, R, M Finch-Jones, Olumide Gbolohon, R Gillmore, R. Gillmore, Roopinder Gillmore

Publications

7.1K

Citations

H-Index

Concepts

All Affiliations

University College London The Royal Free Hospital Hammersmith Hospital University of Manchester The Christie NHS Foundation Trust

About

Roopinder Gillmore is an author at University College London specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	3.2K
2	Health Sciences	3	3	1.7K
3	Public Health	2	2	59
4	Gastroenterology	1	1	16
5	Global Health	1	1	12

Roopinder Gillmore

Publications

6.8K

Citations

H-Index

Page 1

	Year	Citations
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh, The Lancet	2017	1.9K
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study John Primrose, Richard Fox, Daniel H. Palmer, The Lancet Oncology Surgical OncologyGastrointestinal OncologyMedicineCancer ManagementBiliary Cancer	2019	1.2K
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, The Lancet UrologySurgical OncologyGastrointestinal OncologyMedicineBiliary Cancer	2023	891
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan, The Lancet Oncology	2021	711
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization Roopinder Gillmore, Sam Stuart, Amy A. Kirkwood, Journal of Hepatology Surgical OncologyHepatologyMedicineIndependent Prognostic FactorsLiver Disease	2011	322
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma Robert Jones, Eftychia‐Eirini Psarelli, Richard Jackson, JAMA Surgery	2019	256
ABC-06 \| A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan, Journal of Clinical Oncology Cancer ManagementPrognosisPathologyLiver FunctionRobust Evidence	2019	226
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study James J. Harding, Jia Fan, Do‐Youn Oh, The Lancet Oncology MedicineBiliary CancerPathologyPharmacotherapyCancer Treatment	2023	201
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour, The Lancet. Gastroenterology & hepatology Overall SurvivalGastrointestinal OncologyMedicineRandomised Phase 3Biliary Cancer	2024	196
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours Nicholas C. Turner, Sandra J. Strauss, Debashis Sarker, British Journal of Cancer	2010	193

Page 1